Opdivo + Yervoy demonstrates durable overall survival at three years compared to chemotherapy in first-line unresectable malignant pleural mesothelioma – BMS

– Bristol Myers Squibb announced three-year data from the CheckMate -743 trial that demonstrated a durable survival benefit with first-line treatment with Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to platinum-based standard-of-care chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM), regardless of histology. With a minimum follow-up of three years (35.5 months): i Among patients treated with Opdivo plus Yervoy, […]